Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ZIVO Stock Forecast 2026-2027
$9.00
Current Price
$35.00M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ZIVO Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
ZIVO Price Momentum
+28.6%
1 Week Change
-9.8%
1 Month Change
-51.4%
1 Year Change
+3.4%
Year-to-Date Change
-59.1%
From 52W High of $22.00
+29.5%
From 52W Low of $6.95
📊 TOP ANALYST CALLS
Did ZIVO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Zivo is one of their latest high-conviction picks.
Latest ZIVO Stock Price Targets & Analyst Predictions
ZIVO has shown a year-to-date change of 3.4% and a 1-year change of -51.4%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for ZIVO. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ZIVO Analyst Ratings
0
Buy
1
Hold
0
Sell
ZIVO Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $9.00
Latest ZIVO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ZIVO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 4, 2024 | Maxim Group | Anthony Vendetti | Hold | Downgrade | $N/A |
| Dec 15, 2021 | Maxim Group | Anthony Vendetti | Buy | Initiates | $9.00 |
Zivo Bioscience Inc. (ZIVO) Competitors
The following stocks are similar to Zivo based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ZIVO
Zivo Bioscience
mkt cap
35.00M
Zivo Bioscience Inc. (ZIVO) Financial Data
Zivo Bioscience Inc. has a market capitalization of $35.00M with a P/E ratio of -2.1x. The company generates $209,025 in trailing twelve-month revenue with a 31.1% profit margin.
Revenue growth is +108.3% quarter-over-quarter, while maintaining an operating margin of -1,551.8% and return on equity of +2,599.5%.
Valuation Metrics
Market Cap
$35.00M
Enterprise Value
$35.76M
P/E Ratio
-2.1x
PEG Ratio
0.0x
Price/Sales
167.4x
Growth & Margins
Revenue Growth (YoY)
+108.3%
Gross Margin
+32.4%
Operating Margin
-1,551.8%
Net Margin
+31.1%
EPS Growth
+108.3%
Financial Health
Cash/Price Ratio
+0.2%
Current Ratio
0.1x
Debt/Equity
-0.2x
ROE
+2,599.5%
ROA
-1,001.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Zivo Bioscience Inc. (ZIVO) Business Model
About Zivo Bioscience Inc.
What They Do
Biotechnology firm developing innovative nutritional compounds.
Business Model
The company generates revenue by developing and licensing proprietary algal and bacterial strains, along with specialized bioactive compounds, to manufacturers in the nutrition, supplement, and medical food industries. It focuses on creating naturally derived ingredients for both human and animal health, catering to a growing market demand for functional ingredients.
Additional Information
Zivo Bioscience operates in both the biotech and agtech sectors, with applications spanning human dietary supplements, nutraceuticals, food ingredients, and animal feed additives. The company also addresses specific health issues such as poultry gut health, bovine mastitis, canine joint health, and human immune modulation.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
7
CEO
Mr. John Bernard Payne
Country
United States
IPO Year
2003
Website
www.zivobioscience.comZivo Bioscience Inc. (ZIVO) Latest News & Analysis
Latest News
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
4 months ago
Quick Summary
ZIVO Bioscience, Inc. (OTCQB: ZIVO), a biotech company focused on algal-based therapeutic and nutritional products, updated shareholders on its progress and future directions from CEO John B. Payne.
Why It Matters
ZIVO Bioscience's progress in algal-based products highlights potential growth and innovation in biotech, impacting investor sentiment and future valuations.
Source: Business Wire
Market Sentiment:
Neutral
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry
6 months ago
Quick Summary
ZIVO Bioscience, Inc. (OTCQB: ZIVO) has partnered with a major animal health company to develop immune-boosting compounds for the poultry market, with plans for future expansion into other sectors.
Why It Matters
ZIVO's partnership with a leading animal health company could enhance its market potential and revenue streams, signaling growth opportunities in the lucrative poultry sector for investors.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
ZIVO Bioscience, Inc. reported positive results from a study with the University of Delaware on its proprietary ingredients' effectiveness against Low Pathogenicity Avian Influenza virus.
Why It Matters
Positive study results on ZIVO's algal-based products could enhance its market position, attract investment, and drive stock performance amid growing demand for effective avian health solutions.
Source: Business Wire
Market Sentiment:
Neutral
ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry
11 months ago
Quick Summary
ZIVO Bioscience, Inc. (OTCQB: ZIVO) plans a second study with the University of Delaware to investigate its algal-derived ingredients in combating Low Pathogenicity Avian Influenza (LPAI).
Why It Matters
ZIVO's collaboration with the University of Delaware signals potential advancements in antiviral applications, which could enhance product value and market positioning, impacting investor sentiment positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Zivo Bioscience, Inc. (OTCQB: ZIVO) will participate in The Microcap Conference 2025 from January 28-30, 2025, in Atlantic City, presenting its corporate strategy and meeting with investors.
Why It Matters
Zivo Bioscience's participation in The Microcap Conference highlights its growth potential and commitment to investor engagement, which could enhance visibility and attract capital.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Zivo Bioscience, Inc. announced updates on licensing its coccidiosis product for broiler chickens, following positive results from a 42-day study reported in August 2024.
Why It Matters
Zivo Bioscience's licensing update and positive study results for coccidiosis treatments could enhance its market position, potentially increasing revenue and attracting investor interest in biotech innovations.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ZIVO Stock
What is Zivo Bioscience Inc.'s (ZIVO) stock forecast for 2026?
Analyst forecasts for Zivo Bioscience Inc. (ZIVO) are not currently available. The stock is trading at $9.00.
Is ZIVO stock a good investment in 2026?
According to current analyst ratings, ZIVO has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ZIVO stock?
Price predictions from Wall Street analysts for ZIVO are not currently available. The stock is trading at $9.00.
What is Zivo Bioscience Inc.'s business model?
The company generates revenue by developing and licensing proprietary algal and bacterial strains, along with specialized bioactive compounds, to manufacturers in the nutrition, supplement, and medical food industries. It focuses on creating naturally derived ingredients for both human and animal health, catering to a growing market demand for functional ingredients.
What is the highest forecasted price for ZIVO Zivo Bioscience Inc.?
Price targets from Wall Street analysts for ZIVO are not currently available. The stock is trading at $9.00.
What is the lowest forecasted price for ZIVO Zivo Bioscience Inc.?
Price targets from Wall Street analysts for ZIVO are not currently available. The stock is trading at $9.00.
What is the overall ZIVO consensus from analysts for Zivo Bioscience Inc.?
The overall analyst consensus for ZIVO is neutral. Out of 1 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are ZIVO stock price projections?
Stock price projections, including those for Zivo Bioscience Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 19, 2026 5:05 AM UTC